Drugs in Dev. Neurology
IND Enabling
Israel 
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Negev Autism Center Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
SciSparc to Commence its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 14, 2023
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Negev Autism Center Soroka University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SCI-210 is a proprietary combination of cannabidiol (CBD), a non-psychoactive cannabinoid, and PEA, clinical trial will investigate SCI-210 in comparison to CBD monotherapy in treating ASD.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The trial's objectives are to evaluate the safety, tolerability and efficacy of SCI-210 (cannabidiol) in children and adolescents with ASD in a designed 20-week, randomized, double-blind, placebo controlled with a cross-over clinical trial of 60 children...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 08, 2022
Lead Product(s) : Cannabidiol,Cannamide
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IBC-Ab002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $5.0 million
Deal Type : Funding
Details : The grant will be used to support the first-in-human clinical study of IBC-Ab002, a proprietary anti-PD-L1 antibody developed and engineered with differentiating characteristics tailored for the treatment of Alzheimer’s disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
August 27, 2021
Lead Product(s) : IBC-Ab002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : National Institute on Aging
Deal Size : $5.0 million
Deal Type : Funding
Reset All
